search
Back to results

Post Implant Syndrome After EVAR and EVAS (INSPIRE Study)

Primary Purpose

Abdominal Aortic Aneurysm, Inflammatory Response

Status
Withdrawn
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Endovascular Aneurysm Repair (EVAR)
Endovascular Aneurysm Sealing (EVAS)
Sponsored by
Rijnstate Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Abdominal Aortic Aneurysm focused on measuring EVAR, EVAS, Post implant syndrome, Abdominal Aortic Aneurysm

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Elective EVAR/EVAS
  • Ability and willingness to provide written informed consent
  • Age >50 years

Exclusion Criteria:

  • Complex EVAR or EVAS, including iliac branched and supra-renal repairs (pre-planned visceral chimneys, fenestrations or branches)
  • Ruptured or symptomatic AAA
  • Planned internal iliac artery embolization
  • Acute or chronic inflammatory illness (i.e. upper respiratory tract infection)
  • Active rheumatoid arthritis
  • Inflammatory bowel disease, etc.)
  • Inflammatory and mycotic aneurysms
  • Planned associated surgical procedure (i.e. iliac conduit, femoral endarterectomy, etc.)
  • Previous aortic surgery (open or endovascular)
  • Untreated malignancy
  • Major surgery six weeks before EVAR/EVAS
  • Ongoing or recent immunosuppressive treatment, including corticosteroid use

Sites / Locations

  • Marienhospital Kevelaer
  • Rijnstate
  • Auckland City Hospital
  • University Hospital No.1
  • Szpital Wojewódzki nr 4
  • Institution Hematologii I Transfuzjologii,
  • Hospital Universitari I Politècnic La Fe

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Endovascular Aneurysm Repair (EVAR)

Endovascular Aneurysm Sealing (EVAS)

Arm Description

Patients scheduled for EVAR will be included and blood samples at 7 time points will be taken.

Patients scheduled for EVAS will be included and blood samples at 7 time points will be taken.

Outcomes

Primary Outcome Measures

Change in inflammatory response between EVAS and EVAR
The change in early post-operative inflammatory response between EVAS and EVAR, measured by the incidence of the post-implant syndrome.
Change in inflammatory response between EVAS and EVAR
The change in long term inflammatory response between EVAS and EVAR, measured by the incidence of the post-implant syndrome.

Secondary Outcome Measures

Change in aortic thrombus volume
The change in aortic thrombus volume and its relationship with the inflammatory response, measured by cytokines' concentrations.
Pyrexia post operative
Post-operative pyrexia, measured at 24 and 48 hours.
30-day Morbidity
30-day morbidity measured by cytokines' concentrations.
1 year morbidity
1 year morbidity measured by cytokines' concentrations.
Cardiac complications
Cardiac complications (including measures of Troponin T, hsTnT, NT-proBNP) measured by cytokines' concentrations.
Mortality
(all-cause and cardiac) mortality measured by cytokines' concentrations.

Full Information

First Posted
November 13, 2018
Last Updated
March 27, 2019
Sponsor
Rijnstate Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03763812
Brief Title
Post Implant Syndrome After EVAR and EVAS (INSPIRE Study)
Official Title
Explorative Study on the Inflammatory Response After Endovascular Aortic Aneurysm Repair and Endovascular Aneurysm Sealing.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Withdrawn
Why Stopped
Nellix stent cannot be placed in patients yet.
Study Start Date
December 2019 (Anticipated)
Primary Completion Date
December 2020 (Anticipated)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rijnstate Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Retrospective data have shown that active sac management, as applied in EVAS, reduces the incidence of the post-implant syndrome. All-cause and cardiac mortality at one-year seems to be lower after EVAS when compared to EVAR. Ongoing, low grade, inflammation could differ between techniques and induce cardiac damage. This study is designed to establish whether EVAS results in a reduced post-operative inflammatory response during the first year after surgery, compared to EVAR as assessed by trends in circulating inflammatory cytokine concentration. Study design: International prospective, comparative, explorative study. Study population: Patients scheduled to undergo infra-renal EVAR with a polyester endograft or EVAS for an infrarenal aortic aneurysm. This is an explorative study and therefore only patients who would normally receive a suitable device as part of standard treatment at the participating institutes will be recruited. Blood samples will be taken at specified time points before and after surgery. Main study parameters/endpoints: The difference in early post-operative and long term inflammatory response between EVAS and EVAR, measured by the incidence of the post-implant syndrome. To investigate the incidence of the post-implant syndrome, the rise in CRP, WBC and circulating cytokines, at specified time points up to 12 months after surgery and the change in aortic thrombus volume and its relationship with the inflammatory response, measured by cytokines' concentrations.
Detailed Description
Endovascular sealing of abdominal aortic aneurysms (EVAS) is a new technique to treat infrarenal abdominal aortic aneurysms (AAA), which can be performed more expeditiously than endovascular aneurysm repair (EVAR). The difference with EVAR is that fixation and seal are provided from polymer filled endobags that are placed in the aneurysmal sac. The post-implantation syndrome (PIS) is the clinical and biochemical expression of an inflammatory response following endovascular repair of an aortic aneurysm. More specifically, the presence of fever (body temperature >38 C for ≥1 day) and leukocytosis (white blood cell count (WBC) >12.000/mL) with negative blood cultures and is occurring in over 30% cases after EVAR. It is related to prolonged hospital stay and elevated CRP levels, that in turn increase the risk on major adverse cardiac events. The literature showed that the magnitude of the post-operative inflammatory response depends on the type of endoprothesis used for EVAR and that EVAS is related to a lower post-operative CRP level, lower white blood counts, a lower temperature and less cardiac complications compared to standard EVAR. The current study was designed to explore the occurence of the post-implant syndrome after EVAR and EVAS. This study was also designed to unravel the cytokines which are involved in the post-implant syndrome after EVAR and EVAS. In this international, prospective, explorative study 60 patients who are scheduled for EVAR and 60 patients who are scheduled for EVAS will be included. Blood samples (for WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP)) will be taken at: Before induction of anesthesia At wound closure 24 hours after surgery 48 hours after surgery 1 month after surgery 6 months after surgery 12 months after surgery Patients are finished with the study after 12 months of follow-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abdominal Aortic Aneurysm, Inflammatory Response
Keywords
EVAR, EVAS, Post implant syndrome, Abdominal Aortic Aneurysm

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Masking Description
No masking since patients, doctor and researchers know if patients undergo EVAR or EVAS.
Allocation
Non-Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Endovascular Aneurysm Repair (EVAR)
Arm Type
Other
Arm Description
Patients scheduled for EVAR will be included and blood samples at 7 time points will be taken.
Arm Title
Endovascular Aneurysm Sealing (EVAS)
Arm Type
Other
Arm Description
Patients scheduled for EVAS will be included and blood samples at 7 time points will be taken.
Intervention Type
Procedure
Intervention Name(s)
Endovascular Aneurysm Repair (EVAR)
Intervention Description
The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points: Before induction of anesthesia At wound closure 24 hours after surgery 48 hours after surgery 1 month after surgery 6 months after surgery 12 months after surgery
Intervention Type
Procedure
Intervention Name(s)
Endovascular Aneurysm Sealing (EVAS)
Intervention Description
The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points: Before induction of anesthesia At wound closure 24 hours after surgery 48 hours after surgery 1 month after surgery 6 months after surgery 12 months after surgery
Primary Outcome Measure Information:
Title
Change in inflammatory response between EVAS and EVAR
Description
The change in early post-operative inflammatory response between EVAS and EVAR, measured by the incidence of the post-implant syndrome.
Time Frame
Up to 12 months after surgery.
Title
Change in inflammatory response between EVAS and EVAR
Description
The change in long term inflammatory response between EVAS and EVAR, measured by the incidence of the post-implant syndrome.
Time Frame
Up to 12 months after surgery.
Secondary Outcome Measure Information:
Title
Change in aortic thrombus volume
Description
The change in aortic thrombus volume and its relationship with the inflammatory response, measured by cytokines' concentrations.
Time Frame
Up to 12 months after surgery.
Title
Pyrexia post operative
Description
Post-operative pyrexia, measured at 24 and 48 hours.
Time Frame
24 to 48 hours after surgery
Title
30-day Morbidity
Description
30-day morbidity measured by cytokines' concentrations.
Time Frame
Up to 30 days after surgery
Title
1 year morbidity
Description
1 year morbidity measured by cytokines' concentrations.
Time Frame
Up to 12 months after surgery.
Title
Cardiac complications
Description
Cardiac complications (including measures of Troponin T, hsTnT, NT-proBNP) measured by cytokines' concentrations.
Time Frame
Up to 12 months after surgery.
Title
Mortality
Description
(all-cause and cardiac) mortality measured by cytokines' concentrations.
Time Frame
Up to 12 months after surgery.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Elective EVAR/EVAS Ability and willingness to provide written informed consent Age >50 years Exclusion Criteria: Complex EVAR or EVAS, including iliac branched and supra-renal repairs (pre-planned visceral chimneys, fenestrations or branches) Ruptured or symptomatic AAA Planned internal iliac artery embolization Acute or chronic inflammatory illness (i.e. upper respiratory tract infection) Active rheumatoid arthritis Inflammatory bowel disease, etc.) Inflammatory and mycotic aneurysms Planned associated surgical procedure (i.e. iliac conduit, femoral endarterectomy, etc.) Previous aortic surgery (open or endovascular) Untreated malignancy Major surgery six weeks before EVAR/EVAS Ongoing or recent immunosuppressive treatment, including corticosteroid use
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michel Reijnen
Organizational Affiliation
Rijnstate Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Marienhospital Kevelaer
City
Kevelaer
Country
Germany
Facility Name
Rijnstate
City
Arnhem
Country
Netherlands
Facility Name
Auckland City Hospital
City
Auckland
Country
New Zealand
Facility Name
University Hospital No.1
City
Bydgoszcz
Country
Poland
Facility Name
Szpital Wojewódzki nr 4
City
Bytom
Country
Poland
Facility Name
Institution Hematologii I Transfuzjologii,
City
Warsaw
Country
Poland
Facility Name
Hospital Universitari I Politècnic La Fe
City
Valencia
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Post Implant Syndrome After EVAR and EVAS (INSPIRE Study)

We'll reach out to this number within 24 hrs